• Nothing artificial about this intelligence: AI meets IP

    Artificial intelligence (AI) is no longer a plot point in futuristic sci-fi novels and films. In many aspects of our lives, machines are increasingly performing tasks previously handled by human intelligence. The current and potential applications of AI span a breadth of industries… Whether it’s patent search, online advertising or aviation, AI helps by acting as a multiplier for human function and creativity. As humans continue to innovate, producing an overwhelming amount of work which…

    Continue Reading ...
  • Richard A. Catalina, Jr. Joins Wallack LLP

    On NJ October 3, 2017, Hill Wallack LLP announced that they welcomed Richard A. Catalina, Jr. as a partner in the firm’s Princeton, N.J. office. Mr. Catalina is the partner in charge of the firm’s Intellectual Property practice group and is a member of firm’s Life Sciences practice group. Mr. Catalina is a registered patent attorney (45,372) and Certified Licensing Professional™.

    The post Richard A. Catalina, Jr. Joins Wallack LLP appeared first on IPWatchdog.com | Patents & Patent Law.

    Continue Reading ...
  • Saint Regis Mohawk Tribe Outraged at Senator McCaskill over Sovereign Immunity Bill

    McCaskill’s seemingly calculated ploy to get out in front of other Senators, all alone in her demand for a legislative solution that strips Native American Indian Tribes of sovereign immunity, may backfire. The Saint Regis Mohawk Tribe, which acquired the Allergan RESTASIS® patents and then granted back to Allergan an exclusive license, issued a scathing statement.

    The post Saint Regis Mohawk Tribe Outraged at Senator McCaskill over Sovereign Immunity Bill appeared first on IPWatchdog.com |…

    Continue Reading ...
  • Federal Circuit: Antibody-Exception to Written Description Does Not Exist

    By Dennis Crouch Amgen v. Sanofi (Fed. Cir. 2017).  The Delaware district court sided with Patentee Amgen and awarded permanent injunctive relief barring Sanofi from selling its injectable drug product Praulent (alirocaumab) – a human monoclonal antibody used to reduce low-density lipoprotein (LDL) cholesterol – covered by U.S. Patent Nos. 8,829,165 and 8,859,741. On appeal, the Federal Circuit […]

    Continue Reading ...